Franklin Resources
WHWK

Franklin Resources’s Whitehawk Therapeutics WHWK Stock Holding History

Franklin Resources’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,384
Closed -$59.9K – 2740
2023
Q3 		$59.9K Buy
+12,384
New +$72K ﹤0.01% 2517

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Franklin Resources's WHWK Position: Q4 2023 in Review

Franklin Resources sold out of Whitehawk Therapeutics (WHWK) in Q4 2023, closing a stake of 12,384 shares — an estimated $59.9K sold.

Franklin Resources first reported a position in WHWK in Q3 2023 and held it in 1 quarter. The position peaked at $59.9K in Q3 2023. 65 funds tracked by Wall St. Rank hold WHWK as of Q4 2023.

  • Franklin Resources reported no remaining Whitehawk Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Franklin Resources sold 12,384 Whitehawk Therapeutics shares in Q4 2023, an estimated $59.9K.
  • Franklin Resources first reported a position in Whitehawk Therapeutics in Q3 2023 and held it in 1 quarter.
  • Franklin Resources's Whitehawk Therapeutics position peaked at $59.9K in Q3 2023.
  • 65 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q4 2023.

Based on Franklin Resources's 13F filing for Q4 2023, filed 9 Feb 2024.